InvestorsObserver
Sign Up Login

BHVN Biohaven Pharmaceutical Holding

$110.08 $0.00 (0.00%)
Add to Watchlist Compare
Overall

BHVN Stock Analysis Overview

What this means: Biohaven Pharmaceutical Holding (BHVN) gets an Overall Rank of 55, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. BHVN's 55 means that it ranks higher than 55% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

BHVN Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

BHVN Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

BHVN Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

BHVN Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

BHVN Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

BHVN Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

BHVN Stock Analysis Overview

What this means: Biohaven Pharmaceutical Holding (BHVN) gets an Overall Rank of 55, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. BHVN's 55 means that it ranks higher than 55% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full BHVN report

BHVN Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

BHVN Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

BHVN Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

BHVN Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

BHVN Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

BHVN Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Biohaven Pharmaceutical Holding (BHVN) Analyst Forecast

BHVN Price, Volume, Earnings, and Dividend Date

  • Last Price $110.08
  • Previous Close $110.08
  • Change $0.00
  • Open $115.44
  • Volume 904,700
  • Avg. Volume (100-day) 531,081
  • Market Cap 7,210,378,811
  • Days Range 109.94 - 117.35
  • 52-week Range 62.57 - 151.51
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 02/07/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.214
  • PEG Ratio —

Biohaven Pharmaceutical Holding (BHVN) Company Description

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.

Biohaven Pharmaceutical Holding (BHVN) Stock Chart

View Interactive BHVN chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Genfit S.A. ADR (GNFT) (GNFT) $4.47
Verona Pharma Plc ADR (VRNA) (VRNA) $6.37
Tricida Inc (TCDA) (TCDA) $8.81
Fireman B.V. (IFRX) (IFRX) $3.52
Opiant Pharmaceuticals Inc (OPNT) (OPNT) $25.64
Crinetics Pharmaceuticals Inc (CRNX) (CRNX) $18.97
Bellus Health Inc (BLU) (BLU) $5.56
Regeneron Pharmaceuticals (REGN) (REGN) $621.40
Viridian Therapeutics Inc (VRDN) (VRDN) $17.49
Liquidia Corp (LQDA) (LQDA) $5.50